WallStreetZenWallStreetZen

NASDAQ: VTGN
Vistagen Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their VTGN stock forecasts and price targets.

Forecast return on equity

Is VTGN forecast to generate an efficient return?

Company
-73.47%
Industry
82.73%
Market
67.44%
VTGN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VTGN forecast to generate an efficient return on assets?

Company
-64.57%
Industry
23.97%
VTGN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VTGN earnings per share forecast

What is VTGN's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.74
Avg 2 year Forecast
-$2.07

VTGN revenue forecast

What is VTGN's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$1.3M+84.3%
Avg 2 year Forecast
$6.7M+863.91%
VTGN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VTGN revenue growth forecast

How is VTGN forecast to perform vs Biotechnology companies and vs the US market?

Company
210.47%
Industry
136.97%
Market
9.79%
VTGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VTGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VTGN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VTGN$2.46N/AN/A
IGMS$1.18$2.00+69.49%Hold
TCRX$1.24$9.40+658.06%Strong Buy
UNCY$0.60$5.50+822.82%Strong Buy
TNYA$0.45$8.60+1,811.11%Strong Buy
View Top Biotech Stocks

Vistagen Therapeutics Stock Forecast FAQ

What is VTGN's earnings growth forecast for 2026-2027?

(NASDAQ: VTGN) Vistagen Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.01%.

Vistagen Therapeutics's earnings in 2025 is -$47,304,400.On average, 3 Wall Street analysts forecast VTGN's earnings for 2026 to be -$50,124,783, with the lowest VTGN earnings forecast at -$67,537,279, and the highest VTGN earnings forecast at -$37,232,090.

In 2027, VTGN is forecast to generate -$59,600,206 in earnings, with the lowest earnings forecast at -$63,785,208 and the highest earnings forecast at -$55,415,203.

If you're new to stock investing, here's how to buy Vistagen Therapeutics stock.

What is VTGN's revenue growth forecast for 2026-2027?

(NASDAQ: VTGN) Vistagen Therapeutics's forecast annual revenue growth rate of 210.47% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 136.97%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.79%.

Vistagen Therapeutics's revenue in 2025 is $698,300.On average, 1 Wall Street analysts forecast VTGN's revenue for 2026 to be $37,145,503, with the lowest VTGN revenue forecast at $37,145,503, and the highest VTGN revenue forecast at $37,145,503.

In 2027, VTGN is forecast to generate $194,270,694 in revenue, with the lowest revenue forecast at $144,310,425 and the highest revenue forecast at $244,259,825.

What is VTGN's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: VTGN) forecast ROA is -64.57%, which is lower than the forecast US Biotechnology industry average of 23.97%.

What is VTGN's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: VTGN) Vistagen Therapeutics's current Earnings Per Share (EPS) is -$1.48. On average, analysts forecast that VTGN's EPS will be -$1.74 for 2026, with the lowest EPS forecast at -$2.34, and the highest EPS forecast at -$1.29. In 2027, VTGN's EPS is forecast to hit -$2.07 (min: -$2.21, max: -$1.92).

What is VTGN's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: VTGN) forecast ROE is -73.47%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.